ストックスクリーナーアプリを入手
5.28
3.13%
0.16
アフターアワーズ：
5.28
前日終値:
$5.12
開ける：
$5.07
24時間の取引高:
2.81M
Relative Volume:
3.71
時価総額：
$429.68M
収益：
$70.14M
当期純損益:
$-76.24M
株価収益率:
-6.2118
EPS:
-0.85
ネットキャッシュフロー:
$-57.06M
1週間 パフォーマンス:
-4.52%
1か月 パフォーマンス:
+21.94%
6か月 パフォーマンス:
+87.90%
1年 パフォーマンス:
+80.20%
1日の値動き範囲:
$5.07
$5.48
1週間の範囲:
$5.07
$6.0093
52週間の値動き範囲:
$2.53
$6.08
Codexis Inc Stock (CDXS) Company Profile
CDXS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
5.28 | 429.68M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-19 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-05-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-02-29 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-11-07 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-08-07 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 再開されました | Piper Sandler | Overweight |
| 2022-03-02 | 再開されました | Cowen | Outperform |
| 2021-04-12 | 開始されました | Piper Sandler | Overweight |
| 2021-03-01 | 開始されました | Stifel | Buy |
| 2021-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-10 | 開始されました | The Benchmark Company | Buy |
| 2019-01-17 | アップグレード | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | 開始されました | Stephens | Overweight |
| 2017-10-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-05-31 | 開始されました | Jefferies | Buy |
| 2017-01-26 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Codexis Inc (CDXS) 最新ニュース
BNP Paribas Financial Markets Trims Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis (NASDAQ:CDXS) Stock Price Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Codexis's SWOT analysis: enzymatic pioneer's stock poised for RNAi revolution - Investing.com India
Codexis's SWOT analysis: enzymatic pioneer's stock poised for RNAi revolution By Investing.com - Investing.com South Africa
Codexis, Inc.'s (NASDAQ:CDXS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week - Yahoo Finance
Is Codexis (NASDAQ:CDXS) Using Debt In A Risky Way? - Simply Wall St
Jacobs Levy Equity Management Inc. Decreases Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis Announces New Employment Inducement Grants - The Manila Times
Codexis Awards Strategic Equity Package: 208K Shares in Options and RSUs for Key New Hires - StockTitan
Codexis stock soars to 52-week high, touches $4.92 By Investing.com - Investing.com Canada
Codexis stock soars to 52-week high, touches $4.92 - Investing.com India
Global Artificial Sweeteners Market to Observe Growth at a CAGR of ~4% by 2030 | DelveInsight - GlobeNewswire Inc.
Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Fred Alger Management LLC - MarketBeat
Codexis, Inc. (NASDAQ:CDXS) Sees Large Decrease in Short Interest - MarketBeat
Cantor Fitzgerald Reaffirms “Overweight” Rating for Codexis (NASDAQ:CDXS) - Defense World
Codexis's SWOT analysis: enzymatic platform poised to shake up RNAi stock - Investing.com
Codexis (NASDAQ:CDXS) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
GSA Capital Partners LLP Grows Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Deep Dive Into Codexis Stock: Analyst Perspectives (4 Ratings) - Benzinga
Codexis (STU:4QK) EBITDA per Share : €-0.40 (TTM As of Sep. 2024) - GuruFocus.com
Codexis (STU:4QK) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Codexis (STU:4QK) 3-Year FCF Growth Rate : -35.00% (As of Sep. 2024) - GuruFocus.com
Codexis (STU:4QK) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Codexis to Present at Piper Sandler Healthcare Conference in December 2024 | CDXS Stock News - StockTitan
Codexis (NASDAQ:CDXS) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics - GlobeNewswire
Codexis Achieves 98% Efficiency in Breakthrough siRNA Synthesis Platform | CDXS Stock News - StockTitan
Baillie Gifford & Co. Sells 895,002 Shares of Codexis, Inc. (NASDAQ:CDXS) - MarketBeat
Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors - The Manila Times
Codexis adds biotech veteran Raymond De Vré to board - Investing.com India
Codexis Strengthens Board and Updates Bylaws - TipRanks
CDXSCodexis, Inc. Latest Stock News & Market Updates - StockTitan
Codexis adds biotech veteran Raymond De Vré to board By Investing.com - Investing.com UK
Codexis Strengthens Board with Biotech Veteran Raymond De Vré, Former PolyPeptide CEO | CDXS Stock News - StockTitan
Biofuel Enzymes Market Growth Surge: Key Players and Market - openPR
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics - GlobeNewswire
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for - The Bakersfield Californian
Codexis to Showcase Breakthrough RNA Platform, Partners with Bachem at TIDES Europe 2024 | CDXS Stock News - StockTitan
Codexis (CDXS) Grants New Employee 50,000 Stock Options, 15,000 RSUs in Equity Package - StockTitan
Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors - Simply Wall St
Benchmark Downgrades Codexis (CDXS) - MSN
CDXS (Codexis) PE Ratio : At Loss (As of Nov. 06, 2024) - GuruFocus.com
Codexis (FRA:4QK) 3-Year EBITDA Growth Rate : -26.40% (As of Sep. 2024) - GuruFocus.com
Benchmark Reaffirms “Hold” Rating for Codexis (NASDAQ:CDXS) - Defense World
Codexis's SWOT analysis: enzyme engineering firm pivots to RNAi stock By Investing.com - Investing.com Australia
Codexis Inc (CDXS) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):